News | May 14, 2025
GlaxoSmithKline Pharmaceuticals posts FY25 PAT at Rs. 915 Cr
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
ISPP will analyze health systems across states, identifying scalable models and actionable insights to strengthen India's healthcare delivery
he inspection covering the sterile drug product filling and packaging line, quality systems and quality control laboratories concluded compliance with the principles and guidelines of Good Manufacturing Practice
Gelhaus has a proven track record of driving business growth
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
Bayer expects 2025 to be the most difficult year of its turnaround
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Subscribe To Our Newsletter & Stay Updated
